Kinetic modelling of olanzapine interactions with ciprofloxacin and norfloxacin in adult male Wistar rats: unraveling the mechanism of drug-drug interaction

[1] A. Cipriani, JM. Rendell, J. Geddes, Olanzapine in long-term treatment for bipolar disorder, The Cochrane Database of Systematic Reviews 1 (2009) CD004367. DOI: 10.1002/14651858.CD004367.pub2 Search in Google Scholar

[2] K. Komoss, C. Rummel-Kluge, H. Hunger, F. Schmid, S. Schwarz, L. Duggan, W. Kissling, S. Leucht, Olanzapine versus other atypical antipsychotics for schizophrenia, The Cochrane Database of Systematic Reviews 3 (2010) CD006654. DOI: 10.1002/14651858.CD006654.pub2 Search in Google Scholar

[3] P.F. Buckley, Olanzapine: a critical review of recent literature, Expert Opinion on Pharmacotherapy 6 (2005) 2077-2089. DOI: 10.1517/14656566.6.12.2077 Search in Google Scholar

[4] L. Duggan, M. Fenton, J. Rathbone, R. Dardennes, A. El-Dosoky, S. Indran, Olanzapine for schizophrenia, The Cochrane Database of Systematic Reviews 2 (2005) CD001359. DOI: 10.1002/14651858.CD001359.pub2 Search in Google Scholar

[5] E. Vieta, Olanzapine in bipolar disorder, Expert Opinion on Pharmacotherapy 5 (2004) 1613–1619. DOI: 10.1517/14656566.5.7.1613 Search in Google Scholar

[6] B.J. Ring, J. Catlow, T.J. Lindsay, T. Gillespie, L.K. Roskos, B.J. Cerimele, S.P. Swanson, M.A. Hamman, S.A. Wrighton, Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine, The Journal of Pharmacology and Experimental Therapeutics 276 (1996) 658-666. Search in Google Scholar

[7] M.M. Söderberg, M.L. Dahl, Pharmacogenetics of olanzapine metabolism, Pharmacogenomics 14 (2013) 1319-1336. DOi: 10.2217/pgs.13.120 Search in Google Scholar

[8] J. Guo, X. Zhu, S. Badawy, A. Ihsan, Z. Liu, C. Xie, X. Wang, Metabolism and mechanism of human cytochrome P450 enzyme 1A2, Current Drug Metabolism 22 (2021) 40-49. DOI: 10.2174/1389200221999210101233135 Search in Google Scholar

[9] V.K. Jogiraju, T. Heimbach, Y. Toderika, D.R. Taft, Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption, Drug Metabolism and Pharmacokinetics 37 (2021) 100375. DOI: 10.1016/j.dmpk.2020.100375 Search in Google Scholar

[10] T.C. Peterson, M.R. Peterson, P.A. Wornell, M.G. Blanchard, F.J. Gonzalez, Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction, Biochemical Pharmacology 68 (2004) 395-402. DOi: 10.1016/j.bcp.2004.03.035 Search in Google Scholar

[11] T.I. Prior, G.B. Baker, Interactions between the cytochrome P450 system and the second-generation antipsychotics, Journal of Psychiatry & Neuroscience 28 (2003) 99-112. Search in Google Scholar

[12] L. Zhang, M.J. Wei, C.Y. Zhao, H.M. Qi, Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes, Acta Pharmacologica Sinica 29 (2008) 1507-1514. DOI: 10.1111/j.1745-7254.2008.00908.x Search in Google Scholar

[13] M.T. Granfors, J.T. Backman, M. Neuvonen, P.J. Neuvonen, Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism, Clinical Pharmacology and Therapeutics 76 (2004) 598-606. DOI: 10.1016/j.clpt.2004.08.018 Search in Google Scholar

[14] F. Pea, M. Furlanut, Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions, Clinical Pharmacokinetics 40 (2001) 833-868. DOI: 10.2165/00003088-200140110-00004 Search in Google Scholar

[15] A.M. Gheldiu, D.M. Muntean, I. Cristea, I. Antonescu, R. Chira, C. Ureche, L. Vlase, Kinetics of Nebivolol and its active metabolite after single dose oral administration of Nebivolol, Revista de Chimie (Bucharest) 67 (2016) 702-705. Search in Google Scholar

[16] A.M. Gheldiu, A. Csavdari, M. Achim, L. Vlase, I. Tomuță, D. Muntean, Kinetics of zolpidem and its metabolite after single dose oral administration of zolpidem, Studia UBB Chemia LXII (2017) 179-188. DOI: 10.24193/subbchem.2017.2.13 Search in Google Scholar

[17] M. Oroian, A. Marcovici, D.I. Pop, S. Bhardwaj, A. Khuroo, A.M. Gheldiu, L. Vlase, Kinetics of dapagliflozin after single dose oral administration of a 10 mg immediate release tablet, Studia UBB Chemia LXIV (2019) 297-308. DOI: 10.24193/subbchem.2019.2.25 Search in Google Scholar

[18] D.I. Pop, A. Marcovici, M. Oroian, A.M. Gheldiu, L. Vlase, Kinetics of gliclazide after single dose oral administration of gliclazide 60 mg modified release tablet, Studia UBB Chemia LXV (2020) 187-196. DOI: 10.24193/subbchem.2020.2.15 Search in Google Scholar

[19] C. Dansirikul, M. Choi, S.B. Duffull, Estimation of pharmacokinetic parameters from noncompartmental variables using Microsoft Excel, Computers in Biology and Medicine 35 (2005) 389-403. DOI: 10.1016/j.compbiomed.2004.02.008 Search in Google Scholar

[20] W.R. Gillespie, Noncompartmental versus compartmental modelling in clinical pharmacokinetics, Clinical Pharmacokinetics 20 (1991) 253-262. DOI: 10.2165/00003088-199120040-00001 Search in Google Scholar

[21] A. Rescigno, Compartmental analysis and its manifold applications to pharmacokinetics, The AAPS Journal 12 (2010) 61-72. DOI: 10.1208/s12248-009-9160-x Search in Google Scholar

[22] G. Glatting, P. Kletting, S.N. Reske, K. Hohl, C. Ring, Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test, Medical Physics 34 (2007) 4285-4292. DOI: 10.1118/1.2794176 Search in Google Scholar

[23] H. Akaike, A new look at the statistical model identification, IEEE Transactions on Automatic Control 19 (1974) 716-723. DOI: 10.1109/TAC.1974.1100705 Search in Google Scholar